TickerFacts.

Foxo Technologies Inc. (FOXO): Free Cash Flow

Operating cash flow minus capital expenditures for the same annual period and currency, computed by TickerFacts from the filed figures. A simple proxy, not a reported figure; a year without both inputs is left out.

-$3.93M
Year ended 2025-12-31
-$484.5K
Trailing 12 months to 2026-06-30
2021-12-31: -$15.17M2022-12-31: -$23.87M2025-12-31: -$3.93M-$3.93M
2021-12-31 Free Cash Flow (USD) 2025-12-31
Period endedFree Cash FlowChange YoYSource filing
2025-12-31-$3.93Mn/a2026-04-15, From 2025-01-01
No annual figure between 2022-12-31 and 2025-12-31.
2022-12-31-$23.87Mn/m2024-06-06, From 2022-01-01
2021-12-31-$15.17Mn/a2023-03-31, From 2021-01-01

Free Cash Flow at similar companies

Companies with the same SEC industry code (Services-Commercial Physical & Biological Research), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedFree Cash FlowChange YoY
Foxo Technologies Inc. (FOXO)2025-12-31-$3.93Mn/a
OmniAb, Inc. (OABI)2025-12-31-$37.02Mn/m
MaxCyte, Inc. (MXCT)2025-12-31-$36.18Mn/m
bioAffinity Technologies, Inc. (BIAF)2025-12-31-$9.39Mn/m
Absci Corp (ABSI)2025-12-31-$94.03Mn/m
NRC Health (NRC)2025-12-31$15.74M-17.9%
iSpecimen Inc. (ISPC)2025-12-31-$4.24Mn/m
OneMedNet Corp (ONMD)2025-12-31-$7.52Mn/m
Medpace Holdings, Inc. (MEDP)2025-12-31$681.87M+19.2%

Compare FOXO, OABI, MXCT, BIAF side by side · Screen every company in Services-Commercial Physical & Biological Research ↗